Hot Topics Banner

Free Light Chains & Monoclonal Gammopathies

Impact on Diagnostic Panels

August 2008

With the introduction of Mayo’s expanded serum monoclonal protein panel, which includes quantitation of the kappa and lambda free light chains, urine monoclonal protein studies are no longer required as part of the initial diagnostic screen for monoclonal gammopathies. Dr. Katsmann discusses Mayo’s approach to the diagnosis of monoclonal gammopathies and the use of serum free light chain assays.


Print Options

Forward to a Colleague

Share this presentation

If you have questions, email .